Our Transactions
TRANSFORMATIVE TRANSACTIONS AND ENGAGEMENTS
Collaboration + licensing agreement with Sanofi: $27.5M in upfront + preclinical milestones, $400M additional milestones + royalties
Tolerance Therapeutics
Sell-Side M&A Engagement Leading to an Acquisition by Ligand for $20M in Cash
Financing process for Phase 2 Immuno-Oncology Company $45M Private Financing
Japanese Regional Transaction $20M Upfront, $80M Milestone Plus Royalties
Transaction and Corporate Development Advisor $25M Equity Investment with Option to Acquire
NewCo Formation for Thymic Regeneration and Immune Senescence Platforms
Commercial Due Diligence and Advisor for Acquisition $104M Acquisition
Financing process for novel cancer detection technology led to $21M Series A
Japan collaboration for a phase 2 orphan dermatology asset
Licensing agreement for NVK-002 with Zhaoke Ophthalmology in Greater China, South Korea and the Southeast Asian territories
IPO Advisory assignment helping raise $210M in a NASDAQ IPO
Rapid financing process led to oversubscribed crossover financing
A advisor for $340M acquisition and $60M PIPE
Robust Dual-track Process to a Successful $35M Series A Financing
Chinese joint venture to facilitate indication expansion opportunity
Asset sale as part of court-ordered dissolution process
Esteve and Leitat announce strategic partnership to collaborate in research and development
$30M Series A Financing
Sell-side engagement leading to a reverse merger
Asset sale as part of court-ordered dissolution process
Sell-side engagement leading to option agreement for greater Chinese rights
Multi-Track Engagement Leading to Acquisition of Xyphos by Astellas
Rapid M&A Advisory
Exclusive global licensing agreement with SymBio Pharmaceuticals for Brincidofovir
Rapid M&A advisory
Growth capital for point-of-care diagnostic product company $20M Private Placement
Growth capital for automated, rapid microbial detection system for the healthcare product manufacturing sector
Advisor to Pernix in its acquisition of Orexigen Therapeutics for $73.5M
Led sell-side partnering process for a women’s health infectious disease POC diagnostic
Advised on commercial potential of elobixibat in Japan
Exclusive IP licensing agreement
Sell-Side process for NeoCart® leading to a Japan licensing agreement with MEDINET
Facilitated negotiations between the US and Japan leading to the partnering in Japan of Sarilumab
Advised on expansion of existing collaboration on TSX-011 in addition to ASKA equity investment in TesoRx
Advised on Japan buy-side process leading to exclusive License Agreement for Meiji’s carbapenem, SPR-994
Assisted partnership with Maruho including an equity investment from Maruho into Veloce
Advised on company acquisition
Global Multi-Program Immuno-Oncology Alliance
Sell-side Japan/Asia collaboration PRS-080
Sell-side Japan licensing agreement for THG-1001
Sell-Side Process Leading to US licensing agreement for arhalofenate
Buy-side US rights acquisition for Keveyis
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition
Buy-side licensing agreement for ANYARA
Identified and Initiated buy-side acquisition
Sell-side license for Canadian rights of IbuCream
Immuno- Oncology Advisor
Leveraging relationships in Japan to facilitate collaboration to develop and commercialize KHK’s anti-LIGHT mAb.
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share
Facilitating negotiations between US and Japan to speed deal execution.
Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand
Buy-side licensing agreement for ALT1103 for Acromegaly
Series B Financing of $24M
Private Placement of $26.4M
US Option Agreement for IbuCream (topical ibuprofen)
Commercialization agreement for North American rights to Oravig
Buy-side product acquisition of Somatoprim for Acromegaly
Private Placement of $33.2M
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.
Merger between Fabrus and Senesco Technologies
Series A Financing of $7M
US Commercialization Agreement for Sitavig® (acyclovir mucoadhesive tablet)
$62.5 Million Follow on Financing
Worldwide License and Collaboration Agreement
CLIENT: InterMune PARTNER: Vidara TRANSACTION: Actimmune Product Divestiture for $55M upfront plus 2 year royalty
CLIENT: Otsuka PARTNER: Lundbeck TRANSACTION: Worldwide Co-Pro, Co-Dev Agreement for Abilify Depotand OPC-34712
CLIENT: Ascenta PARTNER: Debiopharm Group TRANSACTION: Worldwide Licensing Agreement for AT-406
CLIENT: Angiochem PARTNER: Geron TRANSACTION: Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase
CLIENT: Synthetic Genomics PARTNER: Novartis TRANSACTION: Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring
CLIENT: Strategic Science & Technologies, LLC PARTNER: Undisclosed TRANSACTION: Worldwide Licensing Agreement for IbuCream (topical ibuprofen)
NewCo Formation for Transcription Factor Network Pharmacology Platform
CLIENT: Concordia Pharmaceuticals PARTNER: Ono TRANSACTION: Licensing Agreement for Salirasib in Japan
CLIENT: Synthetic Genomics PARTNER: Novartis TRANSACTION: Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring
CLIENT: Strategic Science & Technologies, LLC PARTNER: Undisclosed TRANSACTION: Worldwide Licensing Agreement for IbuCream (topical ibuprofen)